{
    "id": 1037,
    "name": "lymphoid leukemia",
    "source": "DOID",
    "definition": "A leukemia that has_material_basis_in a B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood. [url:http\\://www.cancer.gov/dictionary?CdrID=616067]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "10747"
    ],
    "termId": "DOID:1037",
    "evidence": [
        {
            "id": 185,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lymphoblastoid cell lines with ATM inactivation derived from ataxia-telangiectasia patients demonstrated increased sensitivity to Lynparza (olaparib) in culture, compared to ATM wild-type cell lines (PMID: 20739657).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1037,
                "name": "lymphoid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 137,
                    "pubMedId": 20739657,
                    "title": "The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20739657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1875,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial which supported FDA approval, Iclusig (ponatinib) was effective in promoting disease regression in 52% of patients with accelerated phase chronic myeloid leukemia, 31% of patients with blast phase chronic myeloid leukemia, and 41% of patients with Philadelphia chromosome positive acute lymphoblastic leukemia (PMID: 23935038).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1037,
                "name": "lymphoid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2374,
                    "pubMedId": 23935038,
                    "title": "Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23935038"
                },
                {
                    "id": 15534,
                    "pubMedId": null,
                    "title": "Iclusig (ponatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1884,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE) that supported FDA approval, Iclusig (ponatinib) resulted in a hematological response in 41% and a major cytogenetic response in 47% of patients with Philadelphia chromosome (BCR-ABL1)-positive acute lymphoblastic leukemia (PMID: 24180494, PMID: 23935038; NCT01207440).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1037,
                "name": "lymphoid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2374,
                    "pubMedId": 23935038,
                    "title": "Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23935038"
                },
                {
                    "id": 5465,
                    "pubMedId": 24180494,
                    "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24180494"
                },
                {
                    "id": 15534,
                    "pubMedId": null,
                    "title": "Iclusig (ponatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00990249",
            "title": "Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2469,
                    "therapyName": "anti-thymocyte globulin + Busulfan + Clofarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01319981",
            "title": "Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                },
                {
                    "id": 770,
                    "therapyName": "Imatinib",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02116777",
            "title": "BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1377,
                    "therapyName": "Talazoparib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02512497",
            "title": "Romidepsin Maintenance After Allogeneic Stem Cell Transplantation",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 8058,
                    "therapyName": "Busulfan + Fludarabine + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02535806",
            "title": "Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1638,
                    "therapyName": "Pegaspargase",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1740,
                    "therapyName": "Mitoxantrone",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03136146",
            "title": "Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 1090,
                    "therapyName": "Ofatumumab",
                    "synonyms": null
                },
                {
                    "id": 1746,
                    "therapyName": "Clofarabine",
                    "synonyms": null
                },
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03592576",
            "title": "Expanded Access to Navitoclax",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 825,
                    "therapyName": "Navitoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03792256",
            "title": "Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8175,
                    "therapyName": "Cytarabine + Hydrocortisone + Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 8217,
                    "therapyName": "Cytarabine + Doxorubicin + Palbociclib + Pegaspargase + Prednisone + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 8218,
                    "therapyName": "Cytarabine + Doxorubicin + Palbociclib + Pegaspargase + Prednisolone + Vincristine",
                    "synonyms": null
                }
            ]
        }
    ]
}